Guardant Health Inc.
Guardant Health, Inc. Announces Results of Annual Stockholder Meeting
Summary
Guardant Health, Inc. held its annual meeting of stockholders on June 18, 2025. All nominees for director were elected, with Vijaya Gadde receiving 95,987,234 votes for, 2,587,247 votes withheld, and 7,173,583 broker non-votes; Roberto Mignone received 97,399,756 votes for, 1,174,725 votes withheld, and 7,173,583 broker non-votes; Myrtle Potter received 96,724,614 votes for, 1,849,867 votes withheld, and 7,173,583 broker non-votes; Musa Tariq received 70,290,715 votes for, 28,283,766 votes withheld, and 7,173,583 broker non-votes. The selection of Deloitte & Touche LLP as the independent registered public accounting firm was ratified with 105,585,947 votes for, 24,506 votes against, and 137,611 abstentions. The advisory vote on executive compensation was approved with 91,189,702 votes for, 7,020,245 votes against, and 364,534 abstentions.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement